Optimizing drugs for local delivery

Drug News and Perspectives

Volumn 22, Issue 10, 2009, Pages 627-634

  Collingwood, S ^a   Lock, R ^a   Searcey, M ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); AMILORIDE; ANGIOGENESIS INHIBITOR; ANTIASTHMATIC AGENT; ANTIOXIDANT; AROMATIC AMIDE; CILOMILAST; CSG 21680; DERMATOLOGICAL AGENT; EPITHELIAL SODIUM CHANNEL BLOCKER; EZETIMIBE; EZTEROL; FLUOCINOLONE ACETONIDE; HYPOCHOLESTEROLEMIC AGENT; PEGAPTANIB; PLASMINOGEN ACTIVATOR INHIBITOR; PROCOLLAGEN C PROTEINASE INHIBITOR; PROTEINASE INHIBITOR; RANIBIZUMAB; SA 58 035; SA 85 035; SCH 47949; SODIUM CHANNEL BLOCKING AGENT; TRIAMCINOLONE; UK 356202; UK 371104; UK 383367; UK 421118; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRY POWDER; HUMAN; IMPLANT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PNEUMONIA; PUMP DESIGN; RETINA MACULA AGE RELATED DEGENERATION; SCAR FORMATION; SKIN SCAR; STOMACH FUNCTION; STOMACH MOTILITY; TOPICAL TREATMENT; TRANSDERMAL DRUG ADMINISTRATION; ULCER; UVEITIS;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77949509798     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.10.1443395     Document Type: Conference Paper

References (7)

1. Lo, R., Kuwahara, K., Li, P-Y., Agrawal, R., Humayun, M.S. and Meng, E. A passive refill able intraocular MEMS drug delivery device. Proceedings of the International Conference on Microtechnologies in Medicine and Biology, Okinawa, Japan, 2006 pp 74-7.
2. Barber, C.G., Dickerson, R.P. and Fish, P.V. Selective urokinase-type plasminogen activa tor (uPA) inhibitors. Part 3: 1-Isoquinolinyl- guanidines. Bioorg Med Chem Lett 2004, 14(12): 3227-30.
3. Bailey, S., Fish, P.V., Billotte, S. et al. Succinyl hydroxamates as potent and selective non- peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg Med Chem Lett 2008, 18(24): 6562-7.
4. Allan, G.A., Gedge, J.I., Nedderman, A.N.R., Roffey, S.J., Small, H.F. and Webster, R. Pharmacokinetics and metabolism of UK- 383,367 in rats and dogs: A rationale for long- lived plasma radioactivity. Xenobiotica 2006, 36(5): 399-418.
5. Knowles, M.R., Church, N.L., Waltner, W.E. et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990, 322(17): 1189-94.
6. 2A receptor ago nists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett 2008, 18(4): 1284-7.
7. 2A ago nists and comparison of inhaled pharmacoki netics in a preclinical model with clinical phar macokinetic data. Bioorg Med Chem Lett 2009, 19(15): 4471-5.